To include your compound in the COVID-19 Resource Center, submit it here.

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

Chinook gains clinical asset for IgA nephropathy while delivering liquidity to its investors

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the merged, public company.

Launched in 2019 with $65 million from Versant Ventures, Apple Tree Partners and Samsara Capital, Chinook Therapeutics Inc. brings to the union preclinical rare disease therapy CHK-336 and clinical asset atrasentan for IgA

Read the full 709 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE